文献速递肿瘤 PET/CT

双环肽放射性示踪剂[68Ga]Ga-BCY18469靶向EphA2的胰腺癌首次人体PET显像:生物分布、剂量学与初步发现

First-in-human EphA2-targeting PET imaging with the bicyclic radiotracer [68Ga]Ga-BCY18469 in pancreatic cancer patients: biodistribution, dosimetry and initial findings.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-06-10

本研究在7例组织学确诊的胰腺导管腺癌患者中开展[68Ga]Ga-BCY18469(靶向EphA2的双环肽PET示踪剂)首次人体显像,评估其安全性、生物分布与剂量学,并与增强CT/MRI对比病灶检出。结果显示无不良事件,肾脏吸收剂量最高,有效剂量为0.017±0.002 mSv/MBq,示踪剂注射后15分钟即见快速肿瘤摄取,45个病灶中PET检出36个。

要点

  • 7例胰腺导管腺癌患者接受[68Ga]Ga-BCY18469 PET/CT,无不良事件发生。
  • 肾脏吸收剂量最高(0.31±0.02 mGy/MBq),有效剂量0.017±0.002 mSv/MBq。
  • 45个病灶中EphA2-PET检出36个,其中11个仅PET检出,9个仅CT/MRI检出。

核心结论

  • [68Ga]Ga-BCY18469可实现安全、快速、高对比度的EphA2表达阳性胰腺导管腺癌病灶显像。
  • 结果支持进一步研究[68Ga]Ga-BCY18469作为EphA2阳性恶性肿瘤诊断工具。

研究设计与样本

  • 首次人体研究,纳入7例组织学确诊的胰腺导管腺癌患者,其中5例化疗后、2例初诊分期。
  • 4例于注射后15、30、45、60和180分钟行PET/CT,3例于注射后45分钟扫描。
  • 基于全身PET采集的器官时间-放射性曲线进行剂量学计算,影像与增强CT或MRI对比(间隔9-50天)。

主要发现

  • 无不良事件报告。
  • 肾脏吸收剂量最高(0.31±0.02 mGy/MBq),有效剂量为0.017±0.002 mSv/MBq。
  • [68Ga]Ga-BCY18469注射后15分钟即见快速肿瘤摄取,主要经肾脏排泄。
  • 45个总病灶中EphA2-PET检出36个可疑转移灶,11个仅EphA2-PET检出,9个仅CT和/或MRI检出。
  • 示踪剂检出13个肝转移灶(SUVmax 6.9±3.4)和13个淋巴结转移灶(SUVmax 5.0±1.1)。

临床怎么用

  • 可考虑将[68Ga]Ga-BCY18469 PET/CT用于EphA2阳性胰腺导管腺癌病灶的显像评估,注射后15分钟即可成像。
  • 阅片时需注意EphA2-PET与CT/MRI存在互补性,部分病灶仅单一模态检出。

局限性

  • 样本量小(7例患者),结果为初步经验,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Erythropoietin-producing hepatocellular receptor A2 (EphA2) is overexpressed in various malignancies, including pancreatic ductal adenocarcinoma (PDAC), in which it correlates with poor prognosis. Although EphA2 is considered a promising target receptor for theranostic applications, suitable radiotracers for clinical imaging have been lacking. This study reports first clinical experiences with [68Ga]Ga-BCY18469, a bicyclic peptide radiotracer for EphA2-targeted PET imaging. METHODS: Seven patients with histologically confirmed PDAC (5 after chemotherapy, 2 at initial staging) underwent PET/CT imaging. Four were scanned at 15, 30, 45, 60 and 180 min. and three at 45 min. after injection of [68Ga]Ga-BCY18469. Dosimetry calculations were performed based on organ-specific time-activity curves from whole-body PET acquisitions. Imaging findings were compared with contrast-enhanced CT or MRI (interval: 9-50 days). RESULTS: No adverse events were observed. The kidneys received the highest absorbed dose (0.31 ± 0.02 mGy/MBq), while the effective dose was 0.017 ± 0.002 mSv/MBq. [68Ga]Ga-BCY18469 demonstrated rapid tumor uptake at 15 min. post-injection with predominantly renal excretion. Of 45 total lesions EphA2-PET detected 36 lesions with tracer uptake suspicious for metastasis. 11 of 45 lesions were detected only on EphA2-PET, whereas 9 of 45 lesions were detected only on CT and/or MRI. The tracer identified 13 liver metastases (SUVmax 6.9 ± 3.4) and 13 lymph node metastases (SUVmax 5.0 ± 1.1), among other findings. CONCLUSIONS: Our initial clinical experiences demonstrate that [68Ga]Ga-BCY18469 enables safe, rapid, and high-contrast visualization of EphA2-expressing PDAC lesions. These results strongly support further investigation of [68Ga]Ga-BCY18469 as a diagnostic tool for EphA2-positive malignancies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Eder AC, Wielenberg CF, Omrane MA, et al. First-in-human EphA2-targeting PET imaging with the bicyclic radiotracer [68Ga]Ga-BCY18469 in pancreatic cancer patients: biodistribution, dosimetry and initial findings. Eur J Nucl Med Mol Imaging. 2026. PMID: 42268404. doi:10.1007/s00259-026-07985-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。